Mylan Pharmaceuticals Inc. has voluntarily recalled 20,112 bottles of Travoprost Ophthalmic Solution (0.004%, 2.5 mL). The recall was initiated after routine stability testing discovered the medication was subpotent and contained impurities or degradation products that exceeded approved safety limits. No injuries or adverse incidents have been reported to date. Consumers should consult their doctor or pharmacist regarding their treatment.
Subpotent medication may not effectively lower eye pressure, potentially leading to inadequate treatment of glaucoma or ocular hypertension. Additionally, the presence of impurities or degradation products beyond specified limits could pose a risk of irritation or other adverse effects.
You have 2 options:
Recall Number: D-0748-2022
If you or a family member were harmed by this recalled product, you may have legal rights. Consider consulting a consumer protection attorney to understand your options for compensation.
This is general information, not legal advice. Go Backs is not a law firm and does not provide legal services.
AI-Enhanced Content: The summary, action steps, and risk assessment on this page were generated by AI from official government recall data to improve readability. This is not legal or medical advice. Always refer to the official agency sources below for authoritative information.
Sources: FDA iRES · Raw API Response
openFDA Disclaimer: This recall information is sourced from the openFDA API. Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. Refer to the openFDA terms of service for more information.